To The Moon

1. $Qualcomm(QCOM)$ QCOM weak 1Q
YoY
Revenue -12% (below their guidance). handsets -18%
Net Income -34%
Dil. EPS -34%
OCF +32%
FCF +50%

2Q guidance
revenue $9.3 B at mid-point (-18% YoY)
EPS $1.63 (-36% at mid-point)QCOM 2Q outlook and 2Q actuals of last year2. $Bristol-Myers Squibb(BMY)$ BMY 4Q weak in-line and new products
4Q YoY
Revenue -5% (Revlimid -$1 B ; -32% )
Net Income -15%
Dil. EPS -11% (Adj -1%)

FY23 Guidance
Revenue +2%

Main BMY weakness from In-Line and New Product
Portfolio

FY22 Guidance of $36 B fell short by ~$0.6BBMY Revlimid fell 32% (YoY) this quarter and 22% for the year
Still had revenue of ~$10B (better than guided $9.0 B to $9.5 B)

FY23 guidance is $6.5 B
So$BMY needs to offset these $3.5 BBMY FY23 guidance

https://twitter.com/DividendWave/status/1621255953826955264